Abstract
Liver transplantation (LT) for hepatocellular carcinoma (HCC) is the treatment of choice for patients with tumor characteristics within the Milan criteria associated with Child B or C cirrhosis. LT provides the best cure for both the tumor and the cirrhosis.
There have been several emerging reports that new-onset diabetes mellitus (NODM) after transplantation (NODAT) is one of the most negative predictive factors for low survival rate and related co-morbidities. Little is known about the onset of NODM in post-transplant patients and, overall, whether the pathogenesis of NODM differs from that known for the general population. Principally, it is still unknown whether NODAT is related to the primary hepatic disease, the surgical procedures, immunosuppressive treatments, or is it due to the donor liver. This review will focus on the identification of factors, in the setting of LT, which may lead to the development of NODM. Early prevention of these factors may abate the incidence of NODM and positively impact survival rate, and thus ameliorate the worsening of cardiovascular risk factors which usually occur after LT.Keywords: Liver transplantation, metabolic syndrome, new-onset diabetes mellitus, HCV, immunosuppressive therapy, nonalcoholic steatohepatitis, insulin resistance, liver surgery
Current Diabetes Reviews
Title:New-onset Diabetes Mellitus: Predictive Factors and Impact on the Outcome of Patients Undergoing Liver Transplantation
Volume: 9 Issue: 1
Author(s): Gerardo Sarno, Rucha J. Mehta, Rodolfo Guardado-Mendoza, Lilia M. Jimenez-Ceja, Paride De Rosa and Giovanna Muscogiuri
Affiliation:
Keywords: Liver transplantation, metabolic syndrome, new-onset diabetes mellitus, HCV, immunosuppressive therapy, nonalcoholic steatohepatitis, insulin resistance, liver surgery
Abstract: Liver transplantation (LT) for hepatocellular carcinoma (HCC) is the treatment of choice for patients with tumor characteristics within the Milan criteria associated with Child B or C cirrhosis. LT provides the best cure for both the tumor and the cirrhosis.
There have been several emerging reports that new-onset diabetes mellitus (NODM) after transplantation (NODAT) is one of the most negative predictive factors for low survival rate and related co-morbidities. Little is known about the onset of NODM in post-transplant patients and, overall, whether the pathogenesis of NODM differs from that known for the general population. Principally, it is still unknown whether NODAT is related to the primary hepatic disease, the surgical procedures, immunosuppressive treatments, or is it due to the donor liver. This review will focus on the identification of factors, in the setting of LT, which may lead to the development of NODM. Early prevention of these factors may abate the incidence of NODM and positively impact survival rate, and thus ameliorate the worsening of cardiovascular risk factors which usually occur after LT.Export Options
About this article
Cite this article as:
Sarno Gerardo, J. Mehta Rucha, Guardado-Mendoza Rodolfo, M. Jimenez-Ceja Lilia, De Rosa Paride and Muscogiuri Giovanna, New-onset Diabetes Mellitus: Predictive Factors and Impact on the Outcome of Patients Undergoing Liver Transplantation, Current Diabetes Reviews 2013; 9 (1) . https://dx.doi.org/10.2174/1573399811309010078
DOI https://dx.doi.org/10.2174/1573399811309010078 |
Print ISSN 1573-3998 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-6417 |
![](/images/wayfinder.jpg)
- Author Guidelines
- Bentham Author Support Services (BASS)
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Opportunistic Pathogens in Diabetic Foot Lesions
Current Diabetes Reviews FOXO1: A Potential Target for Human Diseases
Current Drug Targets Role of Oxidative Stress in the Genesis of Atherosclerosis and Diabetes Mellitus: A Personal Look Back on 50 Years of Research
Current Aging Science Postprandial Hypertriglyceridaemia Revisited in the Era of Non-fasting Lipid Profiles: Executive Summary of a 2019 Expert Panel Statement
Current Vascular Pharmacology Reactive Oxygen Species, Nitric Oxide and Hypertensive Endothelial Dysfunction
Current Hypertension Reviews Mechanism of Action of Novel Glibenclamide Derivatives on Potassium and Calcium Channels for Insulin Secretion
Current Drug Targets Redefining Cardiovascular (CV) Death as a Primary Endpoint Component in Cardiovascular Outcome Trials
Current Diabetes Reviews Editorial [Hot topic: Current Topics on Hypolipidaemic Therapy and Cardiovascular Risk Assessment (Guest Editors: Evangelos C. Rizos and Moses S. Elisaf)]
Current Vascular Pharmacology Proteomic Analysis of Endothelin-1 Targets in the Regulation of Cardiomyocyte Proliferation
Current Topics in Medicinal Chemistry Inhibition of Renin-Angiotensin System and Advanced Glycation End Products Formation: A Promising Therapeutic Approach Targeting on Cardiovascular Diseases
Cardiovascular & Hematological Agents in Medicinal Chemistry Cholesterol Lowering Therapy: Treat to Target or Reduce the Global Risk? The Unresolved Problem of Residual Risk
Current Pharmaceutical Design Cubilin, the Intrinsic Factor-Vitamin B12 Receptor in Development and Disease
Current Medicinal Chemistry Investigating Mitochondrial Dysfunction to Increase Drug Safety in the Pharmaceutical Industry
Current Drug Targets Diabetes-Induced Alterations in Renal Medullary Microcirculation and Metabolism
Current Diabetes Reviews The Possible Hypoglycemic Mechanisms of Echinochrome
Current Diabetes Reviews Generic Clopidogrel Besylate in the Secondary Prevention of Atherothrombotic Events: A 6-month Follow-up of a Randomised Clinical Trial
Current Vascular Pharmacology Subcellular Analysis of the Platelet Proteome
Current Proteomics Biological Role of Formaldehyde, and Cycles Related to Methylation, Demethylation, and Formaldehyde Production
Mini-Reviews in Medicinal Chemistry QSAR Studies of PTP1B Inhibitors: 1, 2-Naphthoquinone Derivatives
Letters in Drug Design & Discovery Emerging Biologics in the Treatment of Inflammatory Bowel Disease: What is Around the Corner?
Current Drug Targets